Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms MANTA-RAy
  • Sponsors Galapagos NV

Most Recent Events

  • 03 Jul 2023 The trial has been completed in Czechia and Estonia (End Date: 10 May 2023), according to European Clinical Trials Database record.
  • 26 May 2023 Number of treatement arms were reduced from 5 to 2 by the merger of- Experimental: Double-Blind Phase: Filgotinib, Extension Phase: Standard of Care and Monitoring Phase: Standard of Care arms, with the existing 2 arms.
  • 26 May 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top